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Abstract
Aim-To investigate whether anaplastic
large cell lymphomas (ALCL) expressing
cytotoxic proteins have a relatively worse
clinical outcome compared with ALCL
lacking a cytotoxic phenotype.
Methods-59 primary cases of ALCL
originating from different sites were in-
vestigated by immunohistochemistry for
the presence of the cytotoxic proteins T
cell intracytoplasmic antigen (TIA-1) and
granzyme B in the neoplastic cells. Since
site of origin and expression of anaplastic
lymphoma kinase (ALK) strongly influ-
ence prognosis, the presence ofa cytotoxic
phenotype was also investigated in rela-
tion to the primary site of origin (lymph
node, gut, or skin) and ALK expression.
The prognostic value was investigated by
analysis of overall and relapse-free sur-
vival time, including Cox regression
analysis.
Results-39 of 59 ALCL (66%) appeared to
have a cytotoxic phenotype as shown by
expression of TIA-1 or granzyme B or
both in the neoplastic cells. The presence
of a cytotoxic phenotype did not have any
influence on prognosis. Even when the
survival data were corrected for site of
origin and stage at presentation or were
analysed separately for ALK positive and
negative cases, no prognostic influence of
a cytotoxic phenotype was observed.
Conclusions-In primary biopsies of pa-
tients with ALCL, the presence of a
cytotoxic phenotype is not related to clini-
cal outcome of the disease.
( Clin Pathol 1999;52:129-136)
Keywords: granzyme B; anaplastic large cell
lymphoma; prognosis
Anaplastic large cell lymphomas (ALCL) are
considered to be a subgroup of non-Hodgkin's
lymphomas (NHL), characterised by the pres-
ence of cohesive sheets of large CD30 positive
anaplastic cells with prominent nucleoli.' At
present only T cell or null cell proliferations are
identified as ALCL in the International
Lymphoma Study Group classification
proposal.2 A consistent finding in a significant
proportion ofALCL cases is the t(2;5) translo-
cation fusing the nucleophosmin gene (NPM)
with a tyrosine kinase gene named anaplastic
lymphoma kinase (ALK), resulting in NPM/
ALK expression. Although the function of this
protein remains unclear,3`6 the presence of
NPM/ALK fusion protein in neoplastic cells of
ALCL cases has been found to be correlated
with a better prognosis.3 6-8
Recent studies indicate that ALCL have
phenotypic features of activated cytotoxic T
cells.9'-2 Using antibodies directed against
granzyme B, perforin, and T cell restricted
intracytoplasmic antigen (TIA-1), it is possible
to detect a population of cells with potential
cytotoxic activity.'3 15 It has been shown that
granzyme B and perforin expression is re-
stricted to activated lymphocytes and natural
killer cells,'6 '7 whereas TIA-1 is found in both
resting and activated cytotoxic T cells and
natural killer cells. In comparison with
granzyme B, TIA-1 is more abundantly
expressed, in up to 60% of CD8 positive lym-
phocytes and in a small minority (6%) of CD4
positive T lymphocytes.'8
It could be hypothesised that lymphomas
originating from cytotoxic T cells (or natural
killer cells) may be particularly resistant to
apoptosis since cytotoxic T cells themselves are
resistant to perforin/granzyme B mediated
lysis. '9 Several mechanisms are likely to be
involved in producing resistance against apop-
tosis of cytotoxic T cells. There is evidence that
an as yet unidentified membrane protein on the
surface of cytotoxic T cells and natural killer
cells protects these cells against perforin medi-
ated lysis.1' Furthermore, in vitro experiments
have shown that (tumour) cells can escape
granzyme B mediated apoptosis by expressing
certain intracellular serine protease inhibitors
(serpins). A recently cloned serpin called PI-9
was shown to be a potent inhibitor of granzyme
B mediated apoptosis.20 These observations
indicate that evasion of granzyme B/perforin
mediated apoptosis might be important in
tumour cell resistance against cytotoxic T cell
mediated cytotoxicity." 21
Although tumour cells showing resistance to
apoptosis induced by cytotoxic T cells are not
inherently also resistant to apoptosis induced
by either radiotherapy or chemotherapy, sev-
eral lines of research indicate that the different
apoptosis inducing signals share one or more
common final lethal pathways.22 24 Thus resist-
ance to cytotoxic T cell induced apoptosis may
also lead to resistance to chemotherapy in-
duced apoptosis, resulting in a poor clinical
outcome in ALCL patients in whom the
tumour cells show a cytotoxic phenotype.
Since the site of origin and ALK expression
strongly influence prognosis,3 2526 we investi-
gated 59 cases of ALCL (44 nodal, three
gastrointestinal, and 12 cutaneous) and
determined whether a cytotoxic phenotype,
alone or in relation to site or ALK expression,
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Table 1 Patient and tumour characteristics at the time offirst presentation in all cases usedfor survival analysis (n = 59)
NodalALCL Gut associatedALCL Cutaneous ALCL
Characteristic GrBITIA-1 pos GrB/TIA-1 neg GrB/TIA-1 pos GrBITIA-1 neg GrBITIA-1 pos GrB/TIA-1 neg
(n=29) (n=15) (n=2) (n=l) (n=8) (n=4)
Median age (y) 39 44 45 74 65 50
Sex (MIF) 19/10 10/5 1/1 0/1 5/3 4/0
Disease stage
I 5 4 0 0 8 4
II 9 4 0 1 0 0
III 7 3 2 0 0 0
IV 8 4 0 0 0 0
B symptoms 14 10 0 1 0 0
CR 24 11 1 1 8 4
Relapse 11 7 2 0 1 2
Cause of death
ALCL 9 6 2 0 0 0
Other 1 0 0 0 2 0
ALCL, anaplastic large cell lymphoma; CR, complete remission; GrB, granzyme B; TIA-1, T cell intracytoplasmic antigen.
influences the clinical behaviour of these sive Cancer Centre, Amsterdam (n = 56) and
lymphomas in terms of overall survival and the St Elizabeth Hospital, Tilburg (n = 3).
relapse-free survival time. ALCL from different sites of origin-that is,
lymph nodes (n = 44), gastrointestinal tract
Methods (n = 3), and skin (n = 12)-were included.
PATIENT SELECTION The diagnosis ofALCL was made according
Paraffin wax embedded tissue specimens of 59 to the criteria of the updated Kiel classification,
primary anaplastic large cell lymphomas were which is also incorporated in the REAL
selected from the archives of the Comprehen- classification.227
Table 2 Patient and tumour characteristics in primary nodal anaplastic large cell lymphomas (ALCL)
Case GrBI TIA-1 * ALK CD3 CD4 CD8 Stage Rx CR Rel Survt Status
Nodal ALCL with a cytotoxic phenotype
1 86 18 + + - - II PC + - 15 AAW
2 60 86 + + - - II PC+R + - 46 AAW
3 47 92 + - nd nd III PC + - 71 AAW
4 30 30 + + + - II PC+R + - 51 AAW
5 30 30 + - +/- - IV PC + - 36 AAW
6 30 30 + - + - I R + + 34 AWD
7 30 30 + - + - III PC + - 27 AAW
8 30 30 + - - - I PC + - 21 AAW
9 10 30 + - - - I PC+R + - 9 AAW
10 7 27 + + + - II PC+R + + 126 AWD
11 1 57 + + - - II PC + - 106 AAW
12 0 72 + - nd - II PC + - 33 AAW
13 92 90 - + - + III PC + + 12 DOD
14 69 38 - + - - III PC + - 64 AAW
15 31 32 - - nd - IV PC + - 207 AAW
16 30 20 - + - - IV PC + - 32 AAW
17 21 44 - + + - IV PC - + 1 DOD
18 20 63 - - + - II PC+R + + 26 DOD
19 20 17 - - nd - III PC+R + + 8 DOD
20 10 30 - - - - IV PC - + 4 DOD
21 10 30 - - + - III PC + + 20 DOD
22 10 10 - - - - I PC + - 54 AAW
23 10 30 - + + - IV PC - + 1 DOD
24 10 25 - - + - IV PC + - 7 DOC
25 10 10 - + +/- - IV PC + - 29 AAW
26 10 10 - - + - II PC - + 2 DOD
27 1 19 - - - - I PC + - 66 AAW
28 0 10 - - + - III PC - + 12 DOD
29 5 74 nd - - - II PC + - 32 AAW
Nodal ALCL without a cytotoxic phenotype
30 0 0 + - + - I PC+R + - 75 AAW
31 0 0 - - + - I PC+R + - 100 AAW
32 0 0 - + - - I R + + 13 DOD
33 0 0 - + nd nd III PC + + 74 AAW
34 0 0 - + + - II PC+R + - 49 AAW
35 0 0 - + - - IV PC + - 44 AAW
36 0 0 - + + - I R + + 25 DOD
37 0 0 - - + - III PC + - 22 AAW
38 0 0 - - - - III PC - + 2 DOD
39 0 0 - - - - IV none - + 0 DOD
40 0 0 - - - - IV none - + 1 DOD
41 0 0 - - + - II PC + - 5 AAW
42 0 0 - - + - II PC + - 12 AAW
43 0 0 - + + nd IV PC - + 3 DOD
44 0 0 nd nd nd nd II PC + - 10 AAW
AAW, alive and well; ALK, anaplastic lymphoma kinase; AWD, alive with disease; CR, complete remission; DOC, died of other
cause; DOD, died of disease; GrB, granzyme B; nd, not determined; PC, polychemotherapy; Rel, relapse; Rx, treatment; Surv,
survival; TIA-1, T cell intracytoplasmic antigen.
*Percentage of positive neoplastic cells determined using the Q-Prodit system.
tSurvival in months.
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Figure 1 Anaplastic large cell lymphoma. (A) A strong granular TIA-1 specific signal (brown) is observed in the
cytoplasm of the large majority of neoplastic cells. (B) A granular dot-like staining ofgranzyme B (brown) in the
neoplastic cells of the same anaplastic large cell lymphoma. (Haematoxylin counterstaining.)
Patient characteristics are summarised in
table 1. The stage of the disease at first presen-
tation was determined by standard staging
procedures including full blood count, x rays of
the chest, computed tomography of the abdo-
men, bone marrow aspiration, and biopsy.
Except in three cases, all patients with nodal
and gut associated tumours received polyche-
motherapy consisting of CHOP (cyclophos-
phamide, doxorubicin, vincristine, and pred-
nisone) or CHOP-like regimens, some
receiving involved field radiation alone (n = 3)
or in addition to chemotherapy (n= 9, table 2).
One patient (No 39, table 2) died before treat-
ment could be given, while another patient (No
40, table 2) declined treatment on personal
grounds. In 49 of the 59 cases, complete
remission was achieved but 23 patients had a
relapse.
IMMUNOHISTOCHEMISTRY
In all cases formalin fixed paraffin embedded
tissue sections were used for immunohisto-
chemical detection of granzyme B and TIA-1.
The antibody raised against TIA- 1 (Coulter
Corporation) recognises a 15 kDa protein in
the cytoplasmic granules of potentially cyto-
toxic T cells and belongs to the IgG1
subclass.'3 28 The production and characterisa-
tion of a granzyme B directed monoclonal
antibody (GB7) has been described
previously.'5 Briefly, the IgG2a subclass mono-
clonal antibody was raised against recombinant
human granzyme B and reacted with granzyme
B isolated from activated human cytotoxic
lymphocytes and natural killer cells. Both
TIA-1 and GB7 can be applied on routine for-
malin fixed, paraffin embedded tissue speci-
mens.
For granzyme B and TIA-1 detection,
sections were boiled in citrate buffer (0.01 M
pH 6.0) using a microwave oven (2 x 5 minutes
at 100°C; maximum power 700 W). They were
then stained with monoclonal antibodies
against granzyme B and TIA-1 (diluted 1:500
and 1:250, respectively) and incubated for one
hour at room temperature, employing a three
step method using a biotinylated rabbit anti-
mouse monoclonal antibody and streptavidin-
biotin-horseradish peroxidase (HRP) complex
(Dako). Cases were further characterised using
antibodies directed against CD3, CD4, CD8,
and CD30 as well as B cell markers (CD20 and
MB2 or CD79a).
ALK expression was detected using the
monoclonal antibody ALKI as described
previously,29 with slight modifications. The
ALK antibody was diluted 1:75 and slides were
incubated overnight at 40C and staining was
enhanced using the CARD method.30
When double staining procedures were
performed (n = 4), granzyme B and TIA-1
were applied simultaneously for 60 minutes at
room temperature. Subsequently TIA-1 was
detected using biotinylated goat anti-IgGl and
GB7 with goat anti-IgG2a conjugated with
HRP and applied simultaneously for 30
minutes. Biotinylated goat anti-IgGI (South-
ern Biotechnology Association) was detected
using streptavidin Cy3 (Jackson Immunore-
search Laboratories) for 90 minutes, while goat
anti-IgG2a HRP was detected by the
deposition of fluorescein isothiocyanate
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Figure 2 Double staining ofgranzyme B and TIA-I in a nodal anaplastic large cell
lymphoma. (A) green staining (FITC conjugated tyramine) indicates granzyme B
expression in neoplastic cells. (B) TIA-1 (red), visualised by cy3 labelled streptavidin.
Tumour cells showing a granular expression of TIA-I in the cytoplasm. (C) Granzyme
BITIA-1 double staining as detected using a triple filter, simultaneously visualising
coexpression of TIA-1 and granzyme B (yellow) and DAPI counterstained nuclei (blue).
(FITC) conjugated tyramine (15 minutes) as
described previously.3" The sections were
counterstained with DAPI and evaluated with
a Leica DMRB fluorescence microscope.
Surrounding reactive lymphocytes were used
as a positive internal control. Negative controls
consisted of simultaneously processed slides
with isotype specific antibodies instead of GB7
and TIA-1, respectively.
RNA IN SITU HYBRIDISATION
To demonstrate that granzyme B positive
staining of tumour cells represented intracellu-
lar production rather than passive uptake from
surrounding non-neoplastic reactive lym-
phocytes, RNA in situ hybridisation (RISH)
was performed to detect granzyme B at the
mRNA level (n = 4). The RISH procedure
used has been described previously.32
INTERPRETATION OF IMMUNOHISTOCHEMICAL
RESULTS
A case was considered to possess a cytotoxic
phenotype when unequivocal staining of neo-
plastic cells (irrespective of the number of
positive cells) for either TIA-1 or granzyme B
was detected according to criteria described by
Foss et al.'" The percentage of tumour cells
staining positive for granzyme B and TIA-1
was quantified using a commercially available
interactive video-overlay based measuring sys-
tem (Q-Prodit, Leica), as described
previously.2" The microscopic image was re-
corded by a charged coupled device camera
and displayed on a monitor. A 40x objective
was used, giving a final magnification of 1 200x,
which appeared the most suitable for this pur-
pose. One hundred fields of vision were
systematically randomly selected using an
automatic scanning stage controlled by
Q-Prodit. In these fields at least 100 tumour
cells, as determined by morphology, were sam-
pled using a Weibel six point test grid (point
distance 50 jim) and scored positive and nega-
tive for granzyme B or TIA- 1.
ANALYSIS OF CLINICAL DATA
For statistical analysis we used 59 biopsies
from primary tumours from which the clinical
data could be retrieved. For each patient the
following characteristics were noted from the
medical records: age, sex, clinical stage at first
presentation, presence of B symptoms, re-
sponse to treatment, occurrence of relapses,
and cause of death. The median follow up time
was 25 months (range 0 to 207 months). Sur-
vival time was measured from the time of initial
diagnosis until death from the disease or until
the date of last follow up. Patients who died of
causes unrelated to the disease were censored
at the time of death. Relapse-free survival time
was measured from time of initial diagnosis
until time of disease relapse. Patients who did
not enter complete remission were assigned a
relapse-free survival time of zero in the
analysis.
STATISTICAL ANALYSIS
Survival curves were constructed with the
Kaplan-Meier method. Differences between
the curves were analysed using the log-rank
test. Cox regression analysis34 (enter and
remove limits 0.1) was used to investigate
whether the percentage of granzyme B/TIA-1
positive tumour cells (when entered as a
continuous variable) was related to prognosis.
Comparisons of means were performed using
the Student t test or the Mann Whitney U test,
where appropriate. Qualitative variables were
analysed by Pearson X2 test or by the Fisher
exact test, where appropriate. All values were
based on two tail statistical analysis. Probability
(p) values below 0.05 were considered signifi-
cant. All analyses were performed using the
SPSS statistical software package.
Results
EXPRESSION OF CYTOTOXIC PROTEINS IN
REACTIVE CELLS IN ALCL
In all cases tested, both granzyme B and TIA-1
positive non-neoplastic small reactive lym-
phocytes were found, thus serving as positive
controls. In these cells a granular staining pat-
tern was observed for either GB7 or TIA-1.
The percentage of reactive lymphocytes
132
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Table 3 Patient and tumour characteristics ofprimary gut associated and cutaneous anaplastic large cell lymphomas
(ALCL)
Case GrB* TM-I * ALK CD3 CD4 CD8 Stage Rx CR Rel Survt Status
Gut associated ALCL with a cytotoxic phenotype
45 90 92 - + - - III PC - + 1 DOD
46 79 88 - + + - III PC + + 13 DOD
Gut associated ALCL without a cytotoxic phenotype
47 0 0 - + + - II PC+R + - 80 AAW
Cutaneous ALCL with a cytotoxic phenotype
48 57 44 - + + - I R + - 16 DOC
49 20 60 - + + - I R + - 13 DOC
50 18 20 - + + - I None + - 68 AAW
51 14 23 - + + - I PC + - 57 AAW
52 11 15 - + + - I PC + - 61 AWD
53 9 15 - +/- + - I PC + + 85 AWD
54 7 17 - + + - I R + - 246 AAW
55 5 11 - + + - I None + - 32 AAW
Cutaneous ALCL without a cytotoxic phenotype
56 0 0 - +/- + - I PC + - 123 AAW
57 0 0 - + - - I PC + + 47 AAW
58 0 0 - + + - I None + + 24 AWD
59 0 0 - - + - I None + - 36 AAW
AAW, alive and well; ALK, anaplastic lymphoma kinase; AWD, alive with disease; CR, complete remission; DOC, died of other
cause; DOD, died of disease; GrB, granzyme B; nd, not determined; PC, polychemotherapy; Rel, relapse; Rx, treatment; Surv,
survival; TIA-1, T cell intracytoplasmic antigen.
*Percentage of positive neoplastic cells determined using the Q-Prodit system.
tSurvival in months.
expressing granzyme B ranged from 1% to
61 %, whereas TIA- 1 expression ranged from
9% to 75% of reactive lymphocytes.
EXPRESSION OF CYTOTOXIC PROTEINS IN
NEOPLASTIC CELLS OF ALCL
In 37 of the 59 cases studied (63%), the
neoplastic cells showed expression of TIA-1
and granzyme B in the tumour cells. In two
additional cases only expression of TIA-1 was
detected. For both TIA-1 and granzyme B, the
characteristic granular or dot-like cytoplasmic
staining in the neoplastic cells was observed
(fig 1). The number of tumour cells staining
positive for either granzyme B or TIA- 1 ranged
from a few positive tumour cells to over 90% of
all tumour cells. All cases positive for granzyme
B were also positive for TIA-1. In all but two
cases, TIA-1 positive tumour cells outnum-
bered the granzyme B positive tumour cells
(table 2). Coexpression ofTIA-1 and granzyme
B in the tumour cells was confirmed using dou-
ble staining procedures, showing colocalisation
of granzyme B and TIA-1 in the cytoplasmic
granules in all four cases tested (fig 2).
CYTOTOXIC PHENOTYPE OF ALCL IN RELATION TO
SITE OF ORIGIN
In nodal ALCL, both TIA-1 and granzyme B
expression was found in tumour cells in 27 of
44 cases (61%), with an additional two cases
showing only TIA-1 expression. In cutaneous
ALCL, expression of both TIA-1 and
granzyme B in tumour cells was found in eight
of 12 cases. In gut associated ALCL, two of
three cases showed a cytotoxic phenotype
(table 3). Thus the cytotoxic phenotype of
ALCL was not associated with a certain site of
origin.
Of the ALCL with a cytotoxic phenotype,
the gut associated ALCL had the highest mean
percentage of neoplastic cells expressing both
TIA-1 and granzyme B, whereas in cutaneous
lymphomas only a minority of the neoplastic
cells showed expression of TIA- 1 or granzyme
B or both. The nodal ALCL cases showed a
highly variable percentage of tumour cells with
a cytotoxic phenotype, ranging from a few to
more than 90% of tumour cells (table 2).
CYTOTOXIC PHENOTYPE OF ALCL IN RELATION TO
ALK EXPRESSION
In nodal ALCL with a cytotoxic phenotype, 12
of 28 cases were ALK positive, compared with
only one ALK positive case of 14 nodal ALCL
without a cytotoxic phenotype (p = 0.02). No
ALK expression was observed in gut associated
and cutaneous cases (table 3).
CYTOTOXIC PHENOTYPE OF ALCL IN RELATION TO
IMMUNOPHENOTYPE
It appeared that with two exceptions, all
primary skin and gut associated ALCL were
CD3+ and CD4+, irrespective of granzyme
B/TIA-1 expression, whereas expression of T
cell markers in nodal ALCL was found to be
more heterogeneous. In nodal granzyme
B/TIA-1 positive cases, five CD3+/CD4+/
CD8- cases were found, six cases positive for
CD3 only, eight positive for CD4 only, one
CD3-/CD4-/CD8+ case, and six CD3-/
CD4-/CD8- cases. These marker profiles did
not differ significantly from nodal granzyme
B/TIA-1 negative cases: three CD3+/CD4+/
CD8- cases, one case positive for CD3 only,
five positive for CD4+ only, and three CD3-/
CD4-/CD8- cases (table 4).
RNA IN SITU HYBRIDISATION
Two cases (one nodal case and one gut associ-
ated ALCL) which were strongly positive for
granzyme B by immunohistochemistry, and
two cases (nodal ALCL) which were negative
for granzyme B, were used for RISH. In these
cases good RNA quality was shown by clear
RISH signals for [2 microglobulin. In both
133
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Table 4 Anaplastic lymphoma kinase (ALK) and Tcell
marker expression on neoplastic cells ofprimary nodal
anaplastic large cell lymphomas (ALCL) with and without
a cytotoxic phenotype
Cytotoxic phenotype ofALCLt
Positive Negative p Value*
ALK (n = 28) (n = 14)
Positive 12 1
Negative 16 13 0.02
CD3 (n = 29) (n = 14)
Positive 11 6
Negative 18 8 NS
CD4 (n = 25) (n = 13)
Positive 13 8
Negative 12 5 NS
CD8 (n = 28) (n = 12)
Positive 1 0
Negative 27 12 NS
tA case was considered to possess a cytotoxic phenotype when
unequivocal staining of neoplastic cells was observed
irrespective of the number of cells staining positive.
*As determined by Pearson x2 test or Fisher exact test.
granzyme B positive cases, granzyme B could
also be demonstrated at the mRNA level in the
neoplastic cells in addition to some reactive
infiltrating lymphocytes (fig 3). In cases with
granzyme B negative tumour cells, no expres-
sion of granzyme B mRNA was detected in the
neoplastic cells, whereas some infiltrating lym-
phocytes did express granzyme B specific
mRNA. These data show that granzyme B
positive staining of tumour cells is not the
result of passive uptake from surrounding non-
neoplastic reactive lymphocytes but represents
intracellular production.
A v j
PATIENT CHARACTERISTICS AND PROGNOSTIC
VALUE OF NEOPLASTIC CELLS WITH A CYTOTOXIC
PHENOTYPE
The clinical features of the 59 patients are
summarised in table 1. When all sites were
included, no major differences in clinical pres-
entation were observed between granzyme
B+/TIA-1+ cases and granzyme B-/TIA-1-
cases. In both groups the majority of patients
were between 25 and 50 years of age, with a
mean of46 years. Also no differences in stage at
presentation were noticed.
Site of first presentation strongly influenced
prognosis (table 5). This ranged from excellent
in all cutaneous cases to moderate in nodal
cases (five year survival 63%). Two of three
patients with a gut associated ALCL died as a
result of the disease. As expected, ALK expres-
sion in nodal cases was found to be a highly
favourable prognostic marker; none of 13
patients with ALK positive ALCL died,
whereas 17 of 44 patients with ALK negative
ALCL died as result of the disease (p = 0.008).
The presence of a cytotoxic phenotype did
not appear to have any impact on prognosis for
either overall survival or relapse-free survival
time when determined by either Cox
regression analysis or by log-rank test. Even
when different arbitrary thresholds for a mini-
mum percentage of tumour cells with a
cytotoxic phenotype was applied (that is, 5%,
10%, 15%, 20%, 30%, or 50% positive tumour
cells), no group with a relatively poor prognosis
could be defined (fig 4). Also, when adjusted
for either stage at presentation, site, or ALK
status, no differences were found in either
overall survival or relapse-free survival time.
B
.I
0
Figure 3 Granzyme B expression at the mRNA level in neoplastic cells using RNA in situ hybridisation. (A) Using an
anti-sense probe, strong black staining is observed in the cytoplasm of the neoplastic cells, indicating the presence of
granzyme B specific mRNA. (B) Sense control (fast nuclear red counterstaining).
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Table 5 Data obtained by univariate
Dec
Characteristic n AL
Cytotoxic phenotype
Positive 39 11
Negative 15 6
ALK
Positive 13 0
Negative 44 17
Stage
I 21 2
II 14 2
III 12 7
IV 12 6
Site
Nodal 44 15
Gastrointestinal 3 2
Cutaneous 12 0
tAs estimated from Kaplan-Meier curves
*Determined by log-rank test.
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survival analysis with a relatively poor prognosis could be
defined. Since (almost) equal percentages were
aths due to Patients alive after 5years**
CL (CO) p Value observed for granzyme B/TIA- 1 positive cases in
nodal, cutaneous, and gut associated lympho-
67 mas, differences in clinical outcome between the
53 NS different sites of origin cannot be ascribed to a
cytotoxic phenotype of the neoplastic cells. In
59 0.008 addition, the fact that nearly all ALK positive
cases (with an excellent prognosis) also show a
90 cytotoxic phenotype further emphasises that a
836 cytotoxic phenotype is not necessarily related to
50 0.0003 a poor clinical outcome.
63 ALCL with a cytotoxic phenotype were33 hardly ever CD8 positive. In only one of 38
100 0.03 tested lymphomas possessing a cytotoxic phe-
notype did the tumour cells express CD8 (a
nodal case), whereas 22 of 35 tested granzyme
B/TIA-1 positive cases were CD4 positive.
However, differences were noted for the differ-
ent sites: all primary granzyme B/TIA-1
Cytotoxic phenotype (n = 29) positive cutaneous cases and one of two gut
associated cases were CD3+/CD4+/CD8-,
whereas granzyme B/TIA-1 positive nodal
ALCL cases showed considerable heterogen-
No cytotoxic phenotype (n = 15) eity in T cell marker phenotype: CD4+/CD8-,CD4-/CD8+, or CD4- and CD8-. The fact
that many granzyme B/TIA- 1 positive cases are
p = 0.27 CD4 rather than CD8 positive is remarkable
l I since in healthy individuals the majority of
0) 12 24 36 48 60 granzyme B/TIA-l positive cytotoxic T lym-
Overall survival (months) phocytes are CD8 positive. Investigation oftumours without T cell marker expression
4 Comparison of overall survival time according reveale thatte ces werea negaior
resence of a cytotoxic phenotype in the neoplastic revealed that these cases were also negative for
primary nodal anaplastic large cell lymphomas. natural killer cell markers CD56 and CD57
(data not shown). The biological relevance of
l survival analysis was performed sepa- CD4 positive cytotoxic T lymphocytes in nor-
for ALK positive and ALK negative mal immune surveillance is still unclear, but
a cytotoxic phenotype did not have any seems limited since these cells are sporadically
-t on clinical outcome. detected in vivo and can be found only after
prolonged cultivation in vitro in the presence of
ission cytokines and antigen.""Ao Recent data indicate
tudy shows that approximately 66% of all that CD4 positive cytotoxic T cells can acquire
L, irrespective of their site of origin, have an activated cytotoxic phenotype in the pres-
totoxic phenotype, indicating that- ence of y interferon at high concentrations.4'
igh the number of gut associated ALCL However, this was only observed in the absence
ll1-the presence of a cytotoxic phenotype of activated CD8 positive cytotoxic T cells.
JCL is not related to the site of origin. Since cutaneous ALCL are consistently
data are in line with those published by CD3/CD4 positive and CD8 negative, these
ics et al and Boulland et al." 15 Interest- lymphomas may be the neoplastic counterparts
the expression ofALK was nearly always of a unique site specific subset of cytotoxic
iated with a cytotoxic phenotype and a CD4 positive T cells,'2 whereas nodal cases
prognosis. This confirms previous find- may originate from different subsets of poten-
hat nodal ALCL showing ALK expres- tially cytotoxic T cells. Another possibility is
is a separate clinicopathological entity that these cases arise from CD4 positive, CD8
l good prognosis.3 Detection of granzyme negative T cells that acquire a cytotoxic pheno-
the mRNA level excluded the possibility type on long term antigenic stimulation or on
letection of granzyme B expression was activation by the presence of high levels of cer-
sult of passive uptake of granzyme B from tain cytokines.42 One indication that cytokine
Lrrounding cytotoxic T cells. levels may be involved in the cytotoxic pheno-
eoretically, the prognosis of ALCL origi- type of tumour cells is the fact that TIA-1 posi-
r from neoplastic equivalents of (activated) tive tumour cells usually outnumbered the
xic T cells should be relatively poor, since number of granzyme B positive tumour cells.
cells are themselves resistant to cytotoxic T Cytotoxic T cells express granzyme B only after
nduced, and possibly also to treatment activation with interleukin (IL)-2, IL-9, or
ed, apoptosis. However, our results clearly IL-i12,"' whereas TIA- 1 is expressed in all
that the presence of a cytotoxic phenotype potentially cytotoxic cells. Thus differences in
aot have any prognostic significance on its local cytokine concentrations might account
Even when several arbitrary thresholds for for the differences in activation stage and thus
limal percentage of tumour cells with a for the different expression patterns for TIA-1
xic phenotype were applied, no group and granzyme B.
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In conclusion, in the majority of cases,
ALCL are a proliferation of CD4 positive T
lymphocytes with an activated cytotoxic phe-
notype. The presence of such a cytotoxic phe-
notype in primary biopsies of patients with
ALCL is not related to site of origin, ALK
expression, or clinical outcome of the disease.
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